| Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia DA Pollyea, BM Stevens, CL Jones, A Winters, S Pei, M Minhajuddin, ... Nature medicine 24 (12), 1859-1866, 2018 | 660 | 2018 |
| MLL-rearranged leukemias—an update on science and clinical approaches AC Winters, KM Bernt Frontiers in pediatrics 5, 4, 2017 | 469 | 2017 |
| Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia S Pei, DA Pollyea, A Gustafson, BM Stevens, M Minhajuddin, R Fu, ... Cancer discovery 10 (4), 536-551, 2020 | 409 | 2020 |
| Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells BM Stevens, CL Jones, DA Pollyea, R Culp-Hill, A D’Alessandro, ... Nature cancer 1 (12), 1176-1187, 2020 | 244 | 2020 |
| Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells CL Jones, BM Stevens, DA Pollyea, R Culp-Hill, JA Reisz, T Nemkov, ... Cell stem cell 27 (5), 748-764. e4, 2020 | 197 | 2020 |
| Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia EM Cherry, D Abbott, M Amaya, C McMahon, M Schwartz, J Rosser, ... Blood advances 5 (24), 5565-5573, 2021 | 154 | 2021 |
| Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia AC Winters, JA Gutman, E Purev, M Nakic, J Tobin, S Chase, J Kaiser, ... Blood advances 3 (20), 2911-2919, 2019 | 146 | 2019 |
| Subversion of systemic glucose metabolism as a mechanism to support the growth of leukemia cells H Ye, B Adane, N Khan, E Alexeev, N Nusbacher, M Minhajuddin, ... Cancer cell 34 (4), 659-673. e6, 2018 | 121 | 2018 |
| The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation ML Amaya, A Inguva, S Pei, C Jones, A Krug, H Ye, M Minhajuddin, ... Blood, The Journal of the American Society of Hematology 139 (4), 584-596, 2022 | 88 | 2022 |
| Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes BM Stevens, N Khan, A D’Alessandro, T Nemkov, A Winters, CL Jones, ... Nature Communications 9 (1), 3694, 2018 | 87 | 2018 |
| Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML … DA Pollyea, A Winters, C McMahon, M Schwartz, CT Jordan, ... Bone Marrow Transplantation 57 (2), 160-166, 2022 | 79 | 2022 |
| Single‐center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia AC Winters, KW Maloney, AL Treece, L Gore, AK Franklin Pediatric Blood & Cancer 67 (10), e28398, 2020 | 68 | 2020 |
| A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy S Pei, IT Shelton, AE Gillen, BM Stevens, M Gasparetto, Y Wang, L Liu, ... Cancer Discovery, CD-22-1297, 2023 | 49 | 2023 |
| CD123 CAR T cells for the treatment of myelodysplastic syndrome BM Stevens, W Zhang, DA Pollyea, A Winters, J Gutman, C Smith, ... Experimental hematology 74, 52-63. e3, 2019 | 43 | 2019 |
| The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells CM Palermo, CA Bennett, AC Winters, CS Hemenway Leukemia research 32 (4), 633-642, 2008 | 42 | 2008 |
| Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax+ Azacitidine Versus … AC Winters, G Bosma, D Abbott, M Minhajuddin, C Jordan, DA Pollyea, ... Transplantation and Cellular Therapy 28 (10), 694. e1-694. e9, 2022 | 38 | 2022 |
| Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse A Kent, DA Pollyea, A Winters, CT Jordan, C Smith, JA Gutman Blood 136, 11-12, 2020 | 29 | 2020 |
| PTPN11 mutations confer unique metabolic properties and increase resistance to venetoclax and azacitidine in acute myelogenous leukemia BM Stevens, CL Jones, A Winters, J Dugan, D Abbott, MR Savona, ... Blood 132, 909, 2018 | 26 | 2018 |
| Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse A Kent, M Schwartz, C McMahon, M Amaya, CA Smith, J Tobin, ... Bone Marrow Transplantation, 1-6, 2023 | 25 | 2023 |
| Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents CA Bennett, AC Winters, NN Barretto, CS Hemenway Leukemia research 33 (7), 937-947, 2009 | 20 | 2009 |
